Latest Targeted therapy Stories
Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29,
- Investigators to Present Clinical Trial Findings Evaluating Compounds in Multiple Tumor Types NORTH CHICAGO, Ill., April 23, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that
LONDON, April 22, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:
Researchers have located a biomarker that they believe could help explain why many of the medications used to treat lung, breast and pancreatic cancers also promote drug resistance and ultimately cause tumors to form in patients.
Improved Overall Survival and Delayed Disease Progression are the Greatest Unmet Needs in this Population, According to Findings from Decision Resources Group BURLINGTON, Mass., April 10, 2014
DUBLIN, April 10, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qxfqmk/drug_delivery_in) has announced the addition of a new report
Metronomic algorithms for targeted therapy to improve value of response and "failed drugs" for "resistant women's cancers" NEW YORK, April 8, 2014 /PRNewswire/ -- The following will
LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:
Dartmouth researchers at its Norris Cotton Cancer Center have compiled a review of the role that information gathered through genetic testing plays in the diagnosis and treatment of breast cancer.
Perjeta and Kadcyla are Reshaping the Treatment Algorithm for Patients with HER2-Positive Breast Cancer, According to Findings from Decision Resources Group BURLINGTON, Mass., March 25, 2014
- An armed gangster.